Back to School: How biopharma can reboot drug development. Access exclusive analysis here

CHMP proposes amending ESA labels

Amgen (AMGN) said that EMEA's CHMP proposed to amend the EU prescribing information for erythropoiesis-stimulating agents (ESAs), including AMGN's

Read the full 190 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE